<DOC>
<DOCNO>EP-0611303</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PREPARATIONS CONTAINING Carboplatin or Lobaplatin FOR ANTI-TUMOUR THERAPY AND/ OR STIMULATING THE HAEMATOPOIETIC SYSTEM
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K9127	A61K4728	A61K4728	A61K3128	A61P3500	A61P3700	A61K3324	A61P3500	A61K31282	A61K3128	A61K9127	A61K3324	A61P3700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61K	A61P	A61K	A61K	A61K	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K9	A61K47	A61K47	A61K31	A61P35	A61P37	A61K33	A61P35	A61K31	A61K31	A61K9	A61K33	A61P37	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
MAX DELBRUECK CENTRUM
</APPLICANT-NAME>
<APPLICANT-NAME>
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
FICHTNER IDUNA
</INVENTOR-NAME>
<INVENTOR-NAME>
RESZKA REGINA
</INVENTOR-NAME>
<INVENTOR-NAME>
FICHTNER, IDUNA
</INVENTOR-NAME>
<INVENTOR-NAME>
RESZKA, REGINA
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of carboplatinum or lobaplatinum in lyotrophic mesophases such as

micellular systems,
microemulsions,
lamellar phases,
hexagonal phases

and/or with other carriers to produce a pharmaceutical agent for the stimulation of the
haematopoietic system.
Use according to claim 1 for the production of a pharmaceutical agent to overcome a
leucopenia caused by cytostatic agents.
Use according to claim 1 for the production of a pharmaceutical agent to stimulate the
haematopoietic system when treating AIDS.
Use according to claims 1 to 3 marked by the fact the pharmaceutical agents are
available in a vesicular form.
Use according to claims 1 to 3 marked by the fact that the pharmaceutical agents are
available in a liposomal form.
Use according to claims 1 to 5 marked by the fact that the pharmaceutical agents
contain


a) mean a natural, semisynthetic or fully synthetic amphilile of the general
formula I



with R
1
 and R
2
 = C
10
 - C
20
 - alkanoyl, -alkenoyl, - alkyl, -alkenyl,
b) a steroid,
c) the anion of biacethyl phosphate, palmitic acid, stearic acid, the anion of
a phospholipid such as phosphatidyl serine, phosphatidic acid, or the

anion of a sphingolipid such as sulphatide,
d) carboplatinum or lobaplatinum
e) a carrier liquid
f) in the case of need, additional auxiliary agents such as nano particles
Use according to claim 6 marked by the fact that the pharmaceutical agents
contain


b) a steroid of the general formula II


with R = H cholesterol

or R = CH
2
- CH
2
 - O - CH
2
 - CH
2
 - OH = diethoxycholesterol.
Use according to claims 6 and 7 marked by the fact that the components are available in
the molar ratio

1:0, 3:0.1 up to 1:1:0.1 or up to 1:1:0.5.
Use according to claims 6 and 7 marked by the fact that the components c:d are
available in the molar ratio between

2:1 and 10:1
</CLAIMS>
</TEXT>
</DOC>
